Biogen
1978
FOUNDED
PUBLIC
STATUS
5K-10K
EMPLOYEES
BIIB
STOCK SYMBOL
56
INVESTMENTS
$229.11
SHARE PRICE
(As of Thursday Closing)
Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
Website
Formerly Known As
Biogen Idec
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 225 Binney Street
- Cambridge, MA 02142
- United States
+1 (781) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Biogen’s full profile, request a free trial.
Biogen Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $216.12 - $388.67 | $44.4B | $235.04 | $23.29 | 2.5M | 194M |
Biogen Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 48,888,522 | 62,864,642 | 68,981,008 | 64,799,671 |
| Revenue | 13,811,600 | 13,452,900 | 12,273,900 | 11,448,800 |
| EBITDA | 7,315,700 | 7,004,300 | 6,382,100 | 5,812,300 |
| Net Income | 4,666,600 | 4,430,700 | 2,539,100 | 3,702,800 |
| Total Assets | 26,445,500 | 25,288,900 | 23,652,600 | 22,876,800 |
| Total Debt | 5,943,200 | 5,936,500 | 5,938,200 | 6,517,400 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Biogen Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Biogen‘s full profile, request access.
Request full access to PitchBookBiogen Competitors (35)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Celgene | Pending Transaction (M&A) | Summit, NJ | 0000 | 000.00 | 000000&0 | 000.00 |
| 000000 00000000000 | Formerly VC-backed | Boston, MA | 0000 | 00.000 | 0000 | 00.000 |
| 0000000 | Formerly VC-backed | Boston, MA | 0000 | 000000000 | ||
| 0000000-00000 0000 | Corporation | New York, NY | 00000 | 00000 | 000000000 | 00000 |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
Biogen Investments & Acquisitions (56)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 | 04-Mar-2019 | 000000000000000000 | 00000 | Biotechnology | 000000 000000000 |
| 0000000 0000000 | 31-Dec-2018 | 000000000 00000000 | 00000 | Biotechnology | 0000000 0000000 |
| 00000000 000 | 24-Jul-2018 | 000000000000000000 | 00000 | Biotechnology | |
| 00000 000000000000 | 11-Jun-2018 | 000000000 00000000 | 000 | Drug Discovery | 000000 000000000 |
| TMS (TMS-007 and Backup Compounds) | 08-Jun-2018 | Corporate Asset Purchase | 0000 | Buildings and Property | 0000000 00000000 |
Biogen Exits (22)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000 00000000000 | 30-Mar-2017 | 00000 00000 00 | 0000 | Completed |
|
| 00000 00 | 03-Nov-2015 | 00000 00000 00 | 000.00 | Completed |
|
| 0000 00000 0000000 | 17-Jun-2014 | 00000 00000 00 | 0000 | Completed |
|
| 0000000 | 17-Mar-2014 | 00000 00000 00 | 0000 | Completed |
|
| Probiodrug | 04-Jan-2012 | Later Stage VC | 000.00 | Completed |
|
Biogen Subsidiaries (4)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| AliveGen USA | Biotechnology | Thousand Oaks, CA | 2014 |
| 00000000000 000000 | Biotechnology | Cambridge, United Kingdom | 0000 |
| 0000000 | Biotechnology | NC | 0000 |
| 0000000 | Biotechnology | South San Francisco, CA | 0000 |
Biogen Executive Team (68)
38 Former Executives
You’re viewing 5 of 68 executives. Get the full list »Biogen Board Members (13)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 000000000 000000 00.0 | Self | Director and Chairman, Corporate Governance Committee | 000 0000 | |
| 00000 000000 | Self | Director & Chairman, Finance Committee | 000 0000 | |
| 00000000 00000 | Biogen | Board Member & Chairman, Audit Committee | 000 0000 | |
| 0000 00000000 00 | Self | Board Member | 000 0000 | |
| 0000 000000 | Biogen | Board Member and Chairman, Risk Committee | 000 0000 |
1 Former Board Member
You’re viewing 5 of 13 board members. Get the full list »